Eli Lilly and Boehringer Ingelheim announced the launch of Basaglar (insulin glargine injection) for use to control high blood sugar in children and adults with type 1 diabetes and adults with type 2 diabetes.
Basaglar is a long-acting insulin with an amino acid sequence that is the same as Lantus, another insulin glargine 100 Units/mL product. It was initially approved by the Food and Drug Administration (FDA) in December 2015.
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake—especially by skeletal muscle and fat—and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Basaglar should not be used to treat diabetic ketoacidosis and should not be used during episodes of hypoglycemia or in patients with allergy to insulin glargine or any of the ingredients in Basaglar.
Basaglar is available as a 100 Units/mL (U-100) strength in 3mL prefilled KwikPens in 5-count cartons.